The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | COVID-19 vaccination in patients with B-cell malignancies after CAR-T therapy
Saurabh Dahiya, MD, University of Maryland School of Medicine, Baltimore, MD, shares the results of a study investigating immunogenicity to COVID-19 vaccination in patients with B-cell malignancies who have received CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study reported that only one of 18 patients was able to mount an antibody immune response demonstrating significant neutralization against COVID-19 antigens. Further analysis revealed that these patients were able to mount an immune response against common infections, suggesting that patients with B-cell malignancies treated with CD19-directed CAR-T therapy can only mount an immune response against previous antigens. Results on T-cell immunogenicity to COVID-19 vaccination are eagerly awaited. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
